| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5657098 | Clinical Gastroenterology and Hepatology | 2017 | 38 Pages |
Abstract
In a systematic review and meta-analysis, we found risk of major GI bleeding to be similar between NOACs and conventional anticoagulation. Dabigatran and rivaroxaban, however, may be associated with increased odds of major GI bleeding. Further high-quality studies are needed to characterize GI bleeding risk among NOACs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Corey S. Miller, Alastair Dorreen, Myriam Martel, Thao Huynh, Alan N. Barkun,